Abstract：Objective: To investigate the effect of Roxadustat on inflammatory mediators and myocardial enzymes in patients with renal anemia. Methods: According to the principle of random number grouping,90 patients with renal anemia admitted from October 2020 to December 2021 were divided into an observation group and a control group,with 45 patients in each group..The patients in the control group were treated with routine anti anemia therapy,while the patients in the observation group were treated with Roxadustat on the basis of the treatment in the control group,and the therapeutic effects,iron metabolism indicators[serum ferritin (SF),transferrin (TRF),transferrin saturation (TSAT),and ferrimodulin (Hepc)],inflammatory mediators[interleukin-6 (IL-6) and C-reactive protein (CRP)] Myocardial zymogram indicators[phosphocreatine kinase (CK),phosphocreatine kinase isoenzyme (CK-MB),lactate dehydrogenase (LDH)] and adverse reactions were compared. Results: The therapeutic effect,SF,TRF and TSAT levels in the observation group were higher than those in the control group (P<0.05).After treatment,the levels of Hepc,IL-6,CRP,CK,CK-MB and LDH in the observation group were lower than those in the control group (P<0.05).There was no statistical difference between the two groups in the incidence of adverse reactions (P>0.05). Conclusion: Rosalrestat has a good effect on patients with renal anemia.It can effectively improve the level of iron metabolism and inflammatory state,and reduce the indexes of myocardial zymogram,but it has little effect on the occurrence of adverse reactions during treatment.
田丽会, 刘飞, 郭红萍, 陈伟. 罗沙司他在肾性贫血患者中的应用及对机体炎性介质和心肌酶谱的影响[J]. 河北医学, 2023, 29(7): 1213-1216.
TIAN Lihui, LIU Fei, GUO Hongping, et al. The Application of Roxadustat in Patients with Renal Anemia and Its Effects on Inflammatory Mediators and Myocardial Enzymes. HeBei Med, 2023, 29(7): 1213-1216.
2023, Vol. 29 
冀公网安备13080202000677号